Mexico

COFEPRIS, operating under the Secretaria de Salud (SSA), is the primary national authority responsible for the regulation, control, and sanitary promotion of health products in Mexico, including pharmaceuticals, medical devices, diagnostics, and digital health solutions. The overarching legal framework is established by the Ley General de Salud and its associated Reglamento de Insumos para la Salud, which define the requirements for market authorization (Registro Sanitario). All health products intended for commercialization in Mexico must obtain a Registro Sanitario prior to market entry, and the process involves technical, safety, and efficacy dossier review by COFEPRIS through its relevant directorates. Depending on the product category, applicants may benefit from expedited pathways such as the recognition of approvals from reference regulatory authorities (e.g., FDA, EMA, Health Canada), which can significantly reduce review timelines.

A legally established local representative or Mexican legal entity is mandatory for all foreign applicants seeking a Registro Sanitario, as COFEPRIS requires a domiciled responsible party for regulatory correspondence and post-market obligations. Dossiers are generally expected to follow CTD (Common Technical Document) structure for pharmaceuticals and adapted technical file formats for medical devices, aligned with international standards such as those from ISO and IMDRF. In recent years, COFEPRIS has undergone institutional reforms aimed at improving transparency, reducing backlogs, and digitizing submission processes through its SINARAS (Sistema Nacional de Registros de la Secretaria de Salud) platform. The agency has also expanded its use of reliance and recognition mechanisms to accelerate approvals for products already authorized in stringent regulatory jurisdictions, reflecting a broader alignment with Pan American Health Organization (PAHO) and international best practices.

Public procurement of health products in Mexico is primarily coordinated through the Instituto Mexicano del Seguro Social (IMSS), the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), and the Secretaria de Salud at the federal level, with state-level health secretariats managing procurement for the uninsured and Seguro Popular successor programs under the INSABI (now IMSS-Bienestar) framework. Large-scale consolidated tenders are conducted through federal mechanisms governed by the Ley de Adquisiciones, Arrendamientos y Servicios del Sector Publico (LAASSP), and product inclusion on the Cuadro Basico y Catalogo de Insumos del Sector Salud is a prerequisite for public procurement eligibility. In recent years, the federal government has implemented centralized purchasing models, including direct agreements with UNOPS (United Nations Office for Project Services) to manage pharmaceutical and medical supply procurement, aiming to reduce costs and increase transparency across the public health system.

The private sector represents a significant and growing channel for health product commercialization in Mexico, with distribution through retail pharmacy chains, private hospital networks, and specialized distributors operating independently of public procurement cycles. International donor and multilateral channels, including PAHO/WHO revolving fund mechanisms and UNICEF supply division agreements, play a limited but relevant role for specific product categories such as vaccines, essential medicines, and diagnostics targeting vulnerable populations. Mexico does not currently enforce a formal local manufacturing preference policy analogous to those seen in some other emerging markets; however, national industrial policy and strategic health security initiatives increasingly encourage domestic production partnerships, technology transfer agreements, and local value-added activities as informal criteria in tender evaluations and policy frameworks.